Pro-drug form (P2PDox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer

Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2- pyrrolinodoxorubicin (P2PDox) with antibodies or antigen-binding fragments thereof (ADCs), with targetable construct peptides or with other targeting molecules that are capable of delivering the P2PDox to a targeted ce...

Full description

Saved in:
Bibliographic Details
Main Authors GOVINDAN SERENGULAM V, MAZZA-FERREIRA CHRISTINE, GOLDENBERG DAVID M, SATHYANARAYAN NALINI, MCBRIDE WILLIAM J
Format Patent
LanguageEnglish
Published 30.12.2015
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2- pyrrolinodoxorubicin (P2PDox) with antibodies or antigen-binding fragments thereof (ADCs), with targetable construct peptides or with other targeting molecules that are capable of delivering the P2PDox to a targeted cell, tissue or pathogen. Once delivered to the target cell, the ADC or peptide conjugate is internalized, a highly toxic 2-pyrrolinodoxorubicin (2- PDox) is released intracellularly. The P2PDox-peptide or ADC conjugates are of use to treat a wide variety of diseases, such as cancer, autoimmune disease or infectious disease.
Bibliography:Application Number: CN201480003456